CALCIMEDICA INC
CALC · NASDAQ
Updated at 2026-10-13 15:18:11
- Today's High
- $1.23
- Today’s Low
- $1.10
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $1.27
- Previous Close
- $1.20
- Volume
- 74.89K
- Market Cap
- $8.22M
- P/E Ratio
- --
- EPS
- $-1.33
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 505 COAST BOULEVARD SOUTH, LA JOLLA, CA, UNITED STATES, 92037
- Country
- US
- Listing Date
- 2020-09-25
- Fiscal Year End
- December
- Shares Outstanding
- 30.74M
- CIK
- 0001534133
- Website
- calcimedica.com
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies that target calcium-dependent pathways to address both acute and chronic health challenges. The company’s lead candidate, CM4620, aims to alleviate severe muscle cramps associated with sickle cell disease, underscoring its focus on meeting critical unmet medical needs. With a robust proprietary technology platform and an expanding pipeline of novel calcium modulators, CalciMedica is well-positioned for significant growth. Backed by an experienced management team and key strategic partnerships, the company presents a compelling investment opportunity within the biopharmaceutical sector.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$4.01M
2026-03-31
$5.6M
2025-12-31
$4.38M
2025-09-30
$5.61M
Net Income
2026-06-30
-$7.65M
2026-03-31
$4.97M
2025-12-31
-$10.76M
2025-09-30
-$7.8M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.45
2026-03-31
$0.30
2025-12-31
$-3.45
2025-09-30
$-0.52
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$7.32M
2026-03-31
$5.3M
2025-12-31
-$10.43M
2025-09-30
-$7.46M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $4.01M | $5.6M | $4.38M | $5.61M |
| Net Income | -$7.65M | $4.97M | -$10.76M | -$7.8M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.45 | $0.30 | $-3.45 | $-0.52 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$7.32M | $5.3M | -$10.43M | -$7.46M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.